SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension

Hypertension (HTN) is a leading cause of cardiovascular disease (CVD). Despite existing therapies, patients with HTN still face substantial risks, due to pre-existing and ongoing end-organ damage due, in part, to inadequate blood pressure (BP) control. SGLT2 inhibitors (SGLT2i) are recommended for both type-2 diabetes and heart failure to reduce morbidity and mortality. SGLT2i reduce BP and might also improve outcomes for HTN by reducing end-organ damage through diverse other actions. However, confirmation that SGLT2i are clinically useful for the management of HTN is required to change guidelines and clinical practice.

NCT Number	NCT06804161
Lead Sponsor	Prof. Dr. med. Ingo Eitel
Conditions	Atrial Hypertension
Enrollment	3,000 participants
Start Date	2025-12-10
Primary Completion	2032-05-30 (estimated)
Study Completion	2032-05-30 (estimated)
Updated on ClinicalTrials.gov	2025-12-22